UNSPSC 51372015: Morphine

This classification denotes an opiate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76I7G6D29C. European Medicines Agency schedules Morphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03332MIG. Morphine generally arises in the molecular formula C17H19NO3. The term MORPHINE is a Hazardous Substances Data Bank designation. Most nations schedule morphine under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE remains the US FDA Preferred Term for this commodity.

Morphine bears US NLM identifiers UMLS ID C0026549 and NCI Concept Code C62051. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(O)CC3)C=CC2O.

UNSPSC 51372015 Morphine is a Commodity-tier code that in practice captures state and local procurement of pharmaceutical products and harm-reduction supplies, though the code's nominal scope and recent solicitation activity show limited direct morphine purchasing. State and local governments are instead using this code to buy naloxone (opioid antagonist), generic multi-source pharmaceuticals distributed through cooperative purchasing agreements, and over-the-counter products for community health and pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and state procurement offices administering multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work spans pharmaceutical sourcing, delivery logistics, and pharmacy benefit program design rather than procurement of morphine itself.

Recent activity shows solicitation across Florida, Texas, Minnesota, and Oregon. In June 2026, Seminole County, Florida issued an IFB (IFB60459723LAS) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, due July 26, 2023. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for establishing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration, on behalf of MMCAP, issued an RFP (S1070000015802) in January 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026. Vendors in MMCAP procurements must work through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act requirements. The code shows limited volume under its nominal morphine scope; recent activity centers on harm-reduction supplies, cooperative purchasing of generic pharmaceuticals, and pharmacy benefit restructuring initiatives.